Role of the tumor microenvironment in the pathogenesis of gastric carcinoma

World Journal of Gastroenterology

Volumn 20, Issue 7, 2014, Pages 1667-1680

  Chung, Hye Won ^a   Lim, Jong Baeck ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Cytokine; Gastric carcinoma; Helicobacter pylori; Inflammation; Tumor microenvironment

Indexed keywords

ANGIOGENIC FACTOR; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE A; GELATINASE B; HYPOXIA INDUCIBLE FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MAMMALIAN TARGET OF RAPAMYCIN; MATRILYSIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3 KINASE; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; CHEMOKINE; CYTOKINE; MATRIX METALLOPROTEINASE;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CELL PROLIFERATION; CHRONIC INFLAMMATION; FIBROBLAST; HELICOBACTER INFECTION; HUMAN; INFLAMMATION; METASTASIS; MORTALITY; PATHOGENESIS; PREVALENCE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; CARCINOMA; CLINICAL TRIAL (TOPIC); CYTOLOGY; GASTRITIS; HELICOBACTER PYLORI; MACROPHAGE; METABOLISM; MICROBIOLOGY; PATHOLOGY; STOMACH MUCOSA; STOMACH TUMOR;

CARCINOMA; CHEMOKINES; CLINICAL TRIALS AS TOPIC; CYTOKINES; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INFLAMMATION; MACROPHAGES; MATRIX METALLOPROTEINASES; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84894239857     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i7.1667     Document Type: Article

References (193)

1. Torpy JM, Lynm C, Glass RM. JAMA patient page. Stomach cancer. JAMA 2010; 303: 1771 [PMID: 20442395 DOI: 10.1001/jama.303.17.1771]
2. Terry MB, Gaudet MM, Gammon MD. The epidemiology of gastric cancer. Semin Radiat Oncol 2002; 12: 111-127 [PMID: 11979413. DOI: 10.1053/srao.30814]
3. Hohenberger P, Gretschel S. Gastric cancer. Lancet 2003; 362: 305-315 [PMID: 12892963 DOI: 10.1016/S0140-6736(03)13975-X]
4. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545 [PMID: 11229684]
5. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007; 121: 2373-2380 [PMID: 17893866 DOI: 10.1002/ijc.23173]
6. Witz IP, Levy-Nissenbaum O. The tumor microenvironment in the post-PAGET era. Cancer Lett 2006; 242: 1-10 [PMID: 16413116. DOI: 10.1016/j.canlet.2005.12.005]
7. Witz IP. Yin-yang activities and vicious cycles in the tumor microenvironment. Cancer Res 2008; 68: 9-13 [PMID: 18172289. DOI: 10.1158/0008-5472.CAN-07-2917]
8. Witz IP. Tumor-microenvironment interactions: dangerous liaisons. Adv Cancer Res 2008; 100: 203-229 [PMID: 18620097 DOI: 10.1016/S0065-230X(08)00007-9]
9. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211-217 [PMID: 15766659 DOI: 10.1016/j.ccr.2005.02.013]
10. Koehne CH, Dubois RN. COX-2 inhibition and colorectal cancer. Semin Oncol 2004; 31: 12-21 [PMID: 15252926 DOI: 10.1053/j.seminoncol.2004.03.041]
11. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369: 1603-1613 [PMID: 17499602. DOI: 10.1016/S0140-6736(07)60747-8]
12. De Wever O, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 2008; 123: 2229-2238 [PMID: 18777559 DOI: 10.1002/ ijc.23925]
13. Xing F, Saidou J, Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed) 2010; 15: 166-179 [PMID: 20036813 DOI: 10.2741/3613]
14. Peek RM, Crabtree JE. Helicobacter infection and gastric neoplasia. J Pathol 2006; 208: 233-248 [PMID: 16362989 DOI: 10.1002/path.1868]
15. Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 2010; 102: 1584-1598 [PMID: 20937991 DOI: 10.1093/jnci/djq366]
16. Ding SZ, Zheng PY. Helicobacter pylori infection induced gastric cancer; advance in gastric stem cell research and the remaining challenges. Gut Pathog 2012; 4: 18 [PMID: 23217022. DOI: 10.1186/1757-4749-4-18]
17. Segal ED, Cha J, Lo J, Falkow S, Tompkins LS. Altered states: involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori. Proc Natl Acad Sci USA 1999; 96: 14559-14564 [PMID: 10588744 DOI: 10.1073/pnas.96.25.14559]
18. Suganuma M, Yamaguchi K, Ono Y, Matsumoto H, Hayashi T, Ogawa T, Imai K, Kuzuhara T, Nishizono A, Fujiki H. TNF-alpha-inducing protein, a carcinogenic factor secreted from H. pylori, enters gastric cancer cells. Int J Cancer 2008; 123: 117-122 [PMID: 18412243 DOI: 10.1002/ijc.23484]
19. Hatakeyama M. Linking epithelial polarity and carcinogenesis by multitasking Helicobacter pylori virulence factor CagA. Oncogene 2008; 27: 7047-7054 [PMID: 19029944 DOI: 10.1038/onc.2008.353]
20. Sharma SA, Tummuru MK, Blaser MJ, Kerr LD. Activation of IL-8 gene expression by Helicobacter pylori is regulated by transcription factor nuclear factor-kappa B in gastric epithelial cells. J Immunol 1998; 160: 2401-2407 [PMID: 9498783]
21. Isomoto H, Mizuta Y, Miyazaki M, Takeshima F, Omagari K, Murase K, Nishiyama T, Inoue K, Murata I, Kohno S. Implication of NF-kappaB in Helicobacter pylori-associated gastritis. Am J Gastroenterol 2000; 95: 2768-2776 [PMID: 11051346]
22. Hatz RA, Rieder G, Stolte M, Bayerdörffer E, Meimarakis G, Schildberg FW, Enders G. Pattern of adhesion molecule expression on vascular endothelium in Helicobacter pylori-associated antral gastritis. Gastroenterology 1997; 112: 1908-1919 [PMID: 9178683 DOI: 10.1053/gast.1997.v112.pm9178683]
23. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5: 297-309 [PMID: 15803156 DOI: 10.1038/nrc1588]
24. Liu XJ, Chen ZF, Li HL, Hu ZN, Liu M, Tian AP, Zhao D, Wu J, Zhou YN, Qiao L. Interaction between cyclooxygenase-2, Snail, and E-cadherin in gastric cancer cells. World J Gastroenterol 2013; 19: 6265-6271 [PMID: 24115825]
25. Williams CS, Smalley W, DuBois RN. Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest 1997; 100: 1325-1329 [PMID: 9294096 DOI: 10.1172/ JCI119651]
26. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501 [PMID: 8521479 DOI: 10.1016/0092-8674(95)90127-2]
27. Jaiswal M, LaRusso NF, Gores GJ. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol 2001; 281: G626-G634 [PMID: 11518674]
28. Goto T, Haruma K, Kitadai Y, Ito M, Yoshihara M, Sumii K, Hayakawa N, Kajiyama G. Enhanced expression of inducible nitric oxide synthase and nitrotyrosinee in gastric mucosa of gastric cancer patients. Clin Cancer Res 1999; 5: 1411-1415 [PMID: 10389926]
29. Murata-Kamiya N, Kurashima Y, Teishikata Y, Yamahashi Y, Saito Y, Higashi H, Aburatani H, Akiyama T, Peek RM, Azuma T, Hatakeyama M. Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. Oncogene 2007; 26: 4617-4626 [PMID: 17237808]
30. Lauren P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49 [PMID: 14320675]
31. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52: 6735-6740 [PMID: 1458460]
32. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444 [PMID: 18650914 DOI: 10.1038/nature07205]
33. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-436 [PMID: 16724054 DOI: 10.1038/nature04870]
34. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-296 [PMID: 15294155 DOI: 10.1016/ j.cell.2004.07.013]
35. Ditsworth D, Zong WX. NF-kappaB: key mediator of inflammation-associated cancer. Cancer Biol Ther 2004; 3: 1214-1216 [PMID: 15611628 DOI: 10.4161/cbt.3.12.1391]
36. Aihara M, Tsuchimoto D, Takizawa H, Azuma A, Wakebe H, Ohmoto Y, Imagawa K, Kikuchi M, Mukaida N, Matsushima K. Mechanisms involved in Helicobacter pylori-induced interleukin-8 production by a gastric cancer cell line, MKN45. Infect Immun 1997; 65: 3218-3224 [PMID: 9234778]
37. Yasumoto K, Okamoto S, Mukaida N, Murakami S, Mai M, Matsushima K. Tumor necrosis factor alpha and interferon gamma synergistically induce interleukin 8 production in a human gastric cancer cell line through acting concurrently on AP-1 and NF-kB-like binding sites of the interleukin 8 gene. J Biol Chem 1992; 267: 22506-22511 [PMID: 1331059]
38. Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Jang JS, Kim MC, Kim KH, Kim SJ, Kim SG, Kim HJ. Clinicopathologic significance of expression of nuclear factor-κB RelA and its target gene products in gastric cancer patients. World J Gastroenterol 2012; 18: 4744-4750 [PMID: 23002344 DOI: 10.3748/wjg.v18. i34.4744]
39. Crone SG, Jacobsen A, Federspiel B, Bardram L, Krogh A, Lund AH, Friis-Hansen L. microRNA-146a inhibits G protein-coupled receptor-mediated activation of NF-κB by targeting CARD10 and COPS8 in gastric cancer. Mol Cancer 2012; 11: 71 [PMID: 22992343 DOI: 10.1186/1476-4598-11-71]
40. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157: 411-421 [PMID: 10934146 DOI: 10.1016/S0002-9440(10)64554-3]
41. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, Johnson RS, Haddad GG, Karin M. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008; 453: 807-811 [PMID: 18432192 DOI: 10.1038/nature06905]
42. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5835 [PMID: 10582706]
43. Zhou J, Schmid T, Schnitzer S, Brüne B. Tumor hypoxia and cancer progression. Cancer Lett 2006; 237: 10-21 [PMID: 16002209. DOI: 10.1016/j.canlet.2005.05.028]
44. Liu L, Ning X, Sun L, Zhang H, Shi Y, Guo C, Han S, Liu J, Sun S, Han Z, Wu K, Fan D. Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci 2008; 99: 121-128 [PMID: 17953712]
45. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov 2003; 2: 803-811 [PMID: 14526383. DOI: 10.1038/nrd1199]
46. Rohwer N, Lobitz S, Daskalow K, Jöns T, Vieth M, Schlag PM, Kemmner W, Wiedenmann B, Cramer T, Höcker M. HIF-1alpha determines the metastatic potential of gastric cancer cells. Br J Cancer 2009; 100: 772-781 [PMID: 19223895 DOI: 10.1038/sj.bjc.6604919]
47. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7: 41-51 [PMID: 17186030 DOI: 10.1038/nri1995]
48. Tye H, Kennedy CL, Najdovska M, McLeod L, McCormack W, Hughes N, Dev A, Sievert W, Ooi CH, Ishikawa TO, Oshima H, Bhathal PS, Parker AE, Oshima M, Tan P, Jenkins BJ. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell 2012; 22: 466-478 [PMID: 23079657 DOI: 10.1016/ j.ccr.2012.08.010]
49. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809 [PMID: 19851315 DOI: 10.1038/nrc2734]
50. Kim DY, Cha ST, Ahn DH, Kang HY, Kwon CI, Ko KH, Hwang SG, Park PW, Rim KS, Hong SP. STAT3 expression in gastric cancer indicates a poor prognosis. J Gastroenterol Hepatol 2009; 24: 646-651 [PMID: 19175826 DOI: 10.1111/ j.1440-1746.2008.05671.x]
51. Ernst M, Najdovska M, Grail D, Lundgren-May T, Buchert M, Tye H, Matthews VB, Armes J, Bhathal PS, Hughes NR, Marcusson EG, Karras JG, Na S, Sedgwick JD, Hertzog PJ, Jenkins BJ. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest 2008; 118: 1727-1738 [PMID: 18431520]
52. Ellmark P, Ingvarsson J, Carlsson A, Lundin BS, Wingren C, Borrebaeck CA. Identification of protein expression signatures associated with Helicobacter pylori infection and gastric adenocarcinoma using recombinant antibody microarrays. Mol Cell Proteomics 2006; 5: 1638-1646 [PMID: 16844680 DOI: 10.1074/mcp.M600170-MCP200]
53. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T, Canli O, Schwitalla S, Matthews V, Schmid RM, Kirchner T, Arkan MC, Ernst M, Greten FR. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009; 15: 91-102 [PMID: 19185844 DOI: 10.1016/j.ccr.2009.01.002]
54. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D, Yu H. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10: 48-54 [PMID: 14702634 DOI: 10.1038/ nm976]
55. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mulé J, Kerr WG, Jove R, Pardoll D, Yu H. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11: 1314-1321 [PMID: 16288283 DOI: 10.1038/nm1325]
56. Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, Drake C, Pardoll D, Yu H. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009; 15: 114-123 [PMID: 19185846 DOI: 10.1016/ j.ccr.2008.12.018]
57. Mantovani G, Macciò A, Madeddu C, Serpe R, Antoni G, Massa E, Dessì M, Panzone F. Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med (Berl) 2010; 88: 85-92 [PMID: 19802504 DOI: 10.1007/s00109-009-0547-z]
58. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007; 356: 2131-2142 [PMID: 17522398 DOI: 10.1056/ NEJMoa067208]
59. Honjo S, Kase S, Osaki M, Ardyanto TD, Kaibara N, Ito H. Cyclooxygenase-2 expression in human gastric tubular adenomas and carcinomas; correlation with intratumoral microvessel density and apoptotic index. Anticancer Res 2004; 24: 1439-1444 [PMID: 15274307]
60. Yoshida K, Yokozaki H, Niimoto M, Ito H, Ito M, Tahara E. Expression of TGF-beta and procollagen type I and type III in human gastric carcinomas. Int J Cancer 1989; 44: 394-398 [PMID: 2777404 DOI: 10.1002/ijc.2910440303]
61. Mahara K, Kato J, Terui T, Takimoto R, Horimoto M, Murakami T, Mogi Y, Watanabe N, Kohgo Y, Niitsu Y. Transforming growth factor beta 1 secreted from scirrhous gastric cancer cells is associated with excess collagen deposition in the tissue. Br J Cancer 1994; 69: 777-783 [PMID: 8142266 DOI: 10.1038/bjc.1994.147]
62. Horimoto M, Kato J, Takimoto R, Terui T, Mogi Y, Niitsu Y. Identification of a transforming growth factor beta-1 activator derived from a human gastric cancer cell line. Br J Cancer 1995; 72: 676-682 [PMID: 7669580 DOI: 10.1038/bjc.1995.393]
63. Maehara Y, Kakeji Y, Kabashima A, Emi Y, Watanabe A, Akazawa K, Baba H, Kohnoe S, Sugimachi K. Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma. J Clin Oncol 1999; 17: 607-614 [PMID: 10080606]
64. Dhanasekaran DN, Johnson GL. MAPKs: function, regulation, role in cancer and therapeutic targeting. Oncogene 2007; 26: 3097-3099 [PMID: 17496908 DOI: 10.1038/sj.onc.1210395]
65. Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 2004; 306: 1506-1507 [PMID: 15567848 DOI: 10.1126/science.1105396]
66. Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, Okayama Y, Oka T, Shirao K. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer 2008; 98: 832-839 [PMID: 18231104 DOI: 10.1038/ sj.bjc.6604211]
67. Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, Ochiai A. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006; 15: 65-71 [PMID: 16328035]
68. Grávalos C, Gómez-Martín C, Rivera F, Alés I, Queralt B, Márquez A, Jiménez U, Alonso V, García-Carbonero R, Sastre J, Colomer R, Cortés-Funes H, Jimeno A. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin Transl Oncol 2011; 13: 179-184 [PMID: 21421462. DOI: 10.1007/s12094-011-0637-6]
69. Zheng Y, Wang L, Zhang JP, Yang JY, Zhao ZM, Zhang XY. Expression of p53, c-erbB-2 and Ki67 in intestinal metaplasia and gastric carcinoma. World J Gastroenterol 2010; 16: 339-344 [PMID: 20082479 DOI: 10.3748/wjg.v16.i3.339]
70. Im SA, Lee KE, Nam E, Kim DY, Lee JH, Han HS, Seoh JY, Park HY, Cho MS, Han WS, Lee SN. Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas. Tumori 2005; 91: 513-521 [PMID: 16457151]
71. Uchino S, Tsuda H, Maruyama K, Kinoshita T, Sasako M, Saito T, Kobayashi M, Hirohashi S. Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with longterm survival of patients. Cancer 1993; 72: 3179-3184 [PMID: 7902202]
72. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Müller W. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cell Oncol 2010; 32: 57-65 [PMID: 20208134]
73. Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review. Int J Cancer 2012; 130: 2845-2856 [PMID: 21780108 DOI: 10.1002/ijc.26292]
74. Byun DS, Cho K, Ryu BK, Lee MG, Park JI, Chae KS, Kim HJ, Chi SG. Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma. Int J Cancer 2003; 104: 318-327 [PMID: 12569555 DOI: 10.1002/ijc.10962]
75. Li VS, Wong CW, Chan TL, Chan AS, Zhao W, Chu KM, So S, Chen X, Yuen ST, Leung SY. Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer 2005; 5: 29 [PMID: 15784156 DOI: 10.1186/1471-2407-5-29]
76. Kang YH, Lee HS, Kim WH. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 2002; 82: 285-291 [PMID: 11896207 DOI: 10.1038/labinvest.3780422]
77. Lee SH, Lee JW, Soung YH, Kim HS, Park WS, Kim SY, Lee JH, Park JY, Cho YG, Kim CJ, Nam SW, Kim SH, Lee JY, Yoo NJ. BRAF and KRAS mutations in stomach cancer. Oncogene 2003; 22: 6942-6945 [PMID: 14534542 DOI: 10.1038/ sj.onc.1206749]
78. Hiyama T, Haruma K, Kitadai Y, Masuda H, Miyamoto M, Tanaka S, Yoshihara M, Shimamoto F, Chayama K. K-ras mutation in helicobacter pylori-associated chronic gastritis in patients with and without gastric cancer. Int J Cancer 2002; 97: 562-566 [PMID: 11807778 DOI: 10.1002/ijc.1644]
79. Kim IJ, Park JH, Kang HC, Shin Y, Park HW, Park HR, Ku JL, Lim SB, Park JG. Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. Hum Genet 2003; 114: 118-120 [PMID: 14513361 DOI: 10.1007/s00439-003-1027-0]
80. Migliore C, Giordano S. Molecular cancer therapy: can our expectation be MET? Eur J Cancer 2008; 44: 641-651 [PMID: 18295476. DOI: 10.1016/j.ejca.2008.01.022]
81. Inoue T, Kataoka H, Goto K, Nagaike K, Igami K, Naka D, Kitamura N, Miyazawa K. Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue. Cancer Sci 2004; 95: 803-808 [PMID: 15504247 DOI: 10.1111/ j.1349-7006.2004.tb02185.x]
82. Oliveira MJ, Costa AC, Costa AM, Henriques L, Suriano G, Atherton JC, Machado JC, Carneiro F, Seruca R, Mareel M, Leroy A, Figueiredo C. Helicobacter pylori induces gastric epithelial cell invasion in a c-Met and type IV secretion system-dependent manner. J Biol Chem 2006; 281: 34888-34896 [PMID: 16990273 DOI: 10.1074/jbc.M607067200]
83. Han ME, Lee YS, Baek SY, Kim BS, Kim JB, Oh SO. Hedgehog signaling regulates the survival of gastric cancer cells by regulating the expression of Bcl-2. Int J Mol Sci 2009; 10: 3033-3043 [PMID: 19742123 DOI: 10.3390/ijms10073033]
84. Allavena P, Mantovani A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol 2012; 167: 195-205 [PMID: 22235995 DOI: 10.1111/j.1365-2249.2011.04515.x]
85. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66: 605-612 [PMID: 16423985 DOI: 10.1158/0008-5472.CAN-05-4005]
86. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124: 263-266 [PMID: 16439202 DOI: 10.1016/ j.cell.2006.01.007]
87. Ohta M, Kitadai Y, Tanaka S, Yoshihara M, Yasui W, Mukaida N, Haruma K, Chayama K. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int J Cancer 2002; 102: 220-224 [PMID: 12397639 DOI: 10.1002/ijc.10705]
88. Ohta M, Kitadai Y, Tanaka S, Yoshihara M, Yasui W, Mukaida N, Haruma K, Chayama K. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int J Oncol 2003; 22: 773-778 [PMID: 12632067]
89. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193: 1285-1294 [PMID: 11390435 DOI: 10.1084/jem.193.11.1285]
90. Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, Edwards AD, Isaacs JD, Lechler RI. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood 2001; 98: 2736-2744 [PMID: 11675346 DOI: 10.1182/ blood.V98.9.2736]
91. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164 [PMID: 7636184]
92. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006; 108: 804-811 [PMID: 16861339 DOI: 10.1182/ blood-2006-02-002774]
93. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003; 9: 4404-4408 [PMID: 14555512]
94. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer 2008; 122: 2286-2293 [PMID: 18224687 DOI: 10.1002/ijc.23392]
95. Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Miyagawa N, Omata H, Fujii H. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 2006; 55: 1064-1071 [PMID: 16328385 DOI: 10.1007/s00262-005-0092-8]
96. Lu X, Liu J, Li H, Li W, Wang X, Ma J, Tong Q, Wu K, Wang G. Conversion of intratumoral regulatory T cells by human gastric cancer cells is dependent on transforming growth factor-β1. J Surg Oncol 2011; 104: 571-577 [PMID: 21695703 DOI: 10.1002/jso.22005]
97. Lin Y, Kikuchi S, Obata Y, Yagyu K. Serum levels of transforming growth factor beta1 are significantly correlated with venous invasion in patients with gastric cancer. J Gastroenterol Hepatol 2006; 21: 432-437 [PMID: 16509870 DOI: 10.1111/ j.1440-1746.2005.03939.x]
98. Vagenas K, Spyropoulos C, Gavala V, Tsamandas AC. TGFbeta1, TGFbeta2, and TGFbeta3 protein expression in gastric carcinomas: correlation with prognostics factors and patient survival. J Surg Res 2007; 139: 182-188 [PMID: 17270215 DOI: 10.1016/j.jss.2006.10.005]
99. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, Roncarolo MG, Levings MK. Activationinduced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007; 19: 345-354 [PMID: 17329235 DOI: 10.1093/intimm/dxm014]
100. Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA. Natural and induced CD4+CD25+ cells educate CD4+CD25-cells to develop suppressive activity: the role of IL-2, TGFbeta, and IL-10. J Immunol 2004; 172: 5213-5221 [PMID: 15100259]
101. Shen LS, Wang J, Shen DF, Yuan XL, Dong P, Li MX, Xue J, Zhang FM, Ge HL, Xu D. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin Immunol 2009; 131: 109-118 [PMID: 19153062 DOI: 10.1016/j.clim.2008.11.010]
102. Maruyama T, Kono K, Mizukami Y, Kawaguchi Y, Mimura K, Watanabe M, Izawa S, Fujii H. Distribution of Th17 cells and FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. Cancer Sci 2010; 101: 1947-1954 [PMID: 20550524 DOI: 10.1111/ j.1349-7006.2010.01624.x]
103. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-348 [PMID: 15882617 DOI: 10.1016/j.cell.2005.02.034]
104. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 2010; 316: 1324-1331 [PMID: 20211171. DOI: 10.1016/j.yexcr.2010.02.045]
105. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004; 432: 332-337 [PMID: 15549095 DOI: 10.1038/nature03096]
106. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR, Polyak K. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004; 6: 17-32 [PMID: 15261139 DOI: 10.1016/j.ccr.2004.06.010]
107. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401 [PMID: 16572188 DOI: 10.1038/nrc1877]
108. Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 2007; 67: 10123-10128 [PMID: 17974953 DOI: 10.1158/0008-5472. CAN-07-3127]
109. Direkze NC, Hodivala-Dilke K, Jeffery R, Hunt T, Poulsom R, Oukrif D, Alison MR, Wright NA. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res 2004; 64: 8492-8495 [PMID: 15574751 DOI: 10.1158/0008-5472.CAN-04-1708]
110. Worthley DL, Ruszkiewicz A, Davies R, Moore S, Nivison-Smith I, Bik To L, Browett P, Western R, Durrant S, So J, Young GP, Mullighan CG, Bardy PG, Michael MZ. Human gastrointestinal neoplasia-associated myofibroblasts can develop from bone marrow-derived cells following allogeneic stem cell transplantation. Stem Cells 2009; 27: 1463-1468 [PMID: 19492298 DOI: 10.1002/stem.63]
111. Semba S, Kodama Y, Ohnuma K, Mizuuchi E, Masuda R, Yashiro M, Hirakawa K, Yokozaki H. Direct cancer-stromal interaction increases fibroblast proliferation and enhances invasive properties of scirrhous-type gastric carcinoma cells. Br J Cancer 2009; 101: 1365-1373 [PMID: 19773759 DOI: 10.1038/sj.bjc.6605309]
112. Hewitt RE, Powe DG, Carter GI, Turner DR. Desmoplasia and its relevance to colorectal tumour invasion. Int J Cancer 1993; 53: 62-69 [PMID: 7677932 DOI: 10.1002/ijc.2910530113]
113. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-1659 [PMID: 3537791 DOI: 10.1056/NEJM198612253152606]
114. Matsumoto T, Kuroda R, Mifune Y, Kawamoto A, Shoji T, Miwa M, Asahara T, Kurosaka M. Circulating endothelial/ skeletal progenitor cells for bone regeneration and healing. Bone 2008; 43: 434-439 [PMID: 18547890 DOI: 10.1016/ j.bone.2008.05.001]
115. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55: 3964-3968 [PMID: 7664263]
116. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T, Horiuchi T, Muraoka R, Iki M. Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas. Cancer Res 1996; 56: 2671-2676 [PMID: 8653715]
117. Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res 1996; 2: 1679-1684 [PMID: 9816116]
118. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. Cancer Res 1986; 46: 467-473 [PMID: 2416426]
119. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6 [PMID: 1688381. DOI: 10.1093/jnci/82.1.4]
120. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996; 77: 858-863 [PMID: 8608475 DOI: 10.1002/(SICI)1097-0142]
121. Kitadai Y, Haruma K, Sumii K, Yamamoto S, Ue T, Yokozaki H, Yasui W, Ohmoto Y, Kajiyama G, Fidler IJ, Tahara E. Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am J Pathol 1998; 152: 93-100 [PMID: 9422527]
122. Tanimoto H, Yoshida K, Yokozaki H, Yasui W, Nakayama H, Ito H, Ohama K, Tahara E. Expression of basic fibroblast growth factor in human gastric carcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol 1991; 61: 263-267 [PMID: 1685819 DOI: 10.1007/BF02890427]
123. Takahashi Y, Bucana CD, Akagi Y, Liu W, Cleary KR, Mai M, Ellis LM. Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. Clin Cancer Res 1998; 4: 429-434 [PMID: 9516932]
124. Amioka T, Kitadai Y, Tanaka S, Haruma K, Yoshihara M, Yasui W, Chayama K. Vascular endothelial growth factor-C expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa. Eur J Cancer 2002; 38: 1413-1419 [DOI: 10.1016/S0959-8049(02)00106-5]
125. Yonemura Y, Endo Y, Fujita H, Fushida S, Ninomiya I, Bandou E, Taniguchi K, Miwa K, Ohoyama S, Sugiyama K, Sasaki T. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res 1999; 5: 1823-1829 [PMID: 10430087]
126. Onogawa S, Kitadai Y, Amioka T, Kodama M, Cho S, Kuroda T, Ochiumi T, Kimura S, Kuwai T, Tanaka S, Chayama K. Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in early gastric carcinoma: correlation with clinicopathological parameters. Cancer Lett 2005; 226: 85-90 [PMID: 16004935 DOI: 10.1016/j.canlet.2004.12.030]
127. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008; 27: 5904-5912 [PMID: 18836471 DOI: 10.1038/onc.2008.271]
128. Cabarcas SM, Mathews LA, Farrar WL. The cancer stem cell niche--there goes the neighborhood? Int J Cancer 2011; 129: 2315-2327 [PMID: 21792897 DOI: 10.1002/ijc.26312]
129. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J, Clouthier SG, Wicha MS. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol 2009; 7: e1000121 [PMID: 19492080 DOI: 10.1371/journal.pbio.1000121]
130. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, Suri P, Wicha MS. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006; 66: 6063-6071 [PMID: 16778178 DOI: 10.1158/0008-5472.CAN-06-0054]
131. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009; 139: 693-706 [PMID: 19878981 DOI: 10.1016/j.cell.2009.10.014]
132. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF, Rabkin CS. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398-402 [PMID: 10746728 DOI: 10.1038/35006081]
133. El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, Stanford JL, Mayne ST, Goedert J, Blot WJ, Fraumeni JF, Chow WH. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003; 124: 1193-1201 [PMID: 12730860 DOI: 10.1016/S0016-5085(03)00157-4]
134. Tu SP, Quante M, Bhagat G, Takaishi S, Cui G, Yang XD, Muthuplani S, Shibata W, Fox JG, Pritchard DM, Wang TC. IFN-γ inhibits gastric carcinogenesis by inducing epithelial cell autophagy and T-cell apoptosis. Cancer Res 2011; 71: 4247-4259 [PMID: 21512143 DOI: 10.1158/0008-5472. CAN-10-4009]
135. Le Y, Zhou Y, Iribarren P, Wang J. Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell Mol Immunol 2004; 1: 95-104 [PMID: 16212895]
136. Luster AD. Chemokines--chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436-445 [PMID: 9459648]
137. Raman D, Baugher PJ, Thu YM, Richmond A. Role of chemokines in tumor growth. Cancer Lett 2007; 256: 137-165 [PMID: 17629396 DOI: 10.1016/j.canlet.2007.05.013]
138. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D. The functional role of the ELR motif in CXC chemokinemediated angiogenesis. J Biol Chem 1995; 270: 27348-27357 [PMID: 7592998 DOI: 10.1074/jbc.270.45.27348]
139. Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 593-609 [PMID: 16046180 DOI: 10.1016/ j.cytogfr.2005.04.007]
140. Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett 2008; 267: 226-244 [PMID: 18579287 DOI: 10.1016/ j.canlet.2008.04.050]
141. Crabtree JE, Farmery SM, Lindley IJ, Figura N, Peichl P, Tompkins DS. CagA/cytotoxic strains of Helicobacter pylori and interleukin-8 in gastric epithelial cell lines. J Clin Pathol 1994; 47: 945-950 [PMID: 7962609 DOI: 10.1136/jcp.47.10.945]
142. Beales IL, Calam J. Stimulation of IL-8 production in human gastric epithelial cells by Helicobacter pylori, IL-1beta and TNF-alpha requires tyrosinee kinase activity, but not protein kinase C. Cytokine 1997; 9: 514-520 [PMID: 9237814 DOI: 10.1006/cyto.1996.0195]
143. Bäckhed F, Torstensson E, Seguin D, Richter-Dahlfors A, Rokbi B. Helicobacter pylori infection induces interleukin-8 receptor expression in the human gastric epithelium. Infect Immun 2003; 71: 3357-3360 [PMID: 12761119 DOI: 10.1128/ IAI.71.6.3357-3360.2003]
144. Beswick EJ, Das S, Pinchuk IV, Adegboyega P, Suarez G, Yamaoka Y, Reyes VE. Helicobacter pylori-induced IL-8 production by gastric epithelial cells up-regulates CD74 expression. J Immunol 2005; 175: 171-176 [PMID: 15972644]
145. Konturek PC, Nikiforuk A, Kania J, Raithel M, Hahn EG, Mühldorfer S. Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett' s esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors. Dig Dis Sci 2004; 49: 1075-1083 [PMID: 15387324]
146. Macrì A, Versaci A, Loddo S, Scuderi G, Travagliante M, Trimarchi G, Teti D, Famulari C. Serum levels of interleukin 1beta, interleukin 8 and tumour necrosis factor alpha as markers of gastric cancer. Biomarkers 2006; 11: 184-193 [PMID: 16766394. DOI: 10.1080/13547500600565677]
147. Kitadai Y, Haruma K, Mukaida N, Ohmoto Y, Matsutani N, Yasui W, Yamamoto S, Sumii K, Kajiyama G, Fidler IJ, Tahara E. Regulation of disease-progression genes in human gastric carcinoma cells by interleukin 8. Clin Cancer Res 2000; 6: 2735-2740 [PMID: 10914718]
148. Opdenakker G, Van den Steen PE, Dubois B, Nelissen I, Van Coillie E, Masure S, Proost P, Van Damme J. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 2001; 69: 851-859 [PMID: 11404367]
149. Taguchi A, Ohmiya N, Shirai K, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, Goto H. Interleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in Japan. Cancer Epidemiol Biomarkers Prev 2005; 14: 2487-2493 [PMID: 16284368 DOI: 10.1158/1055-9965.EPI-05-0326]
150. Ye BD, Kim SG, Park JH, Kim JS, Jung HC, Song IS. The interleukin-8-251 A allele is associated with increased risk of noncardia gastric adenocarcinoma in Helicobacter pyloriinfected Koreans. J Clin Gastroenterol 2009; 43: 233-239 [PMID: 18542040. DOI: 10.1097/MCG.0b013e3181646701]
151. Song JH, Kim SG, Jung SA, Lee MK, Jung HC, Song IS. The interleukin-8-251 AA genotype is associated with angiogenesis in gastric carcinogenesis in Helicobacter pylori-infected Koreans. Cytokine 2010; 51: 158-165 [PMID: 20621718 DOI: 10.1016/j.cyto.2010.05.001]
152. Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, Janowska-Wieczorek A, Ratajczak J, Ratajczak MZ. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005; 23: 879-894 [PMID: 15888687 DOI: 10.1634/stemcells.2004-0342]
153. Zheng K, Li HY, Su XL, Wang XY, Tian T, Li F, Ren GS. Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J Exp Clin Cancer Res 2010; 29: 31 [PMID: 20380740 DOI: 10.1186/1756-9966-29-31]
154. Lee HJ, Kim SW, Kim HY, Li S, Yun HJ, Song KS, Kim S, Jo DY. Chemokine receptor CXCR4 expression, function, and clinical implications in gastric cancer. Int J Oncol 2009; 34: 473-480 [PMID: 19148483]
155. Zhao BC, Zhao B, Han JG, Ma HC, Wang ZJ. Adiposederived stem cells promote gastric cancer cell growth, migration and invasion through SDF-1/CXCR4 axis. Hepatogastroenterology 2010; 57: 1382-1389 [PMID: 21443090]
156. Zhao BC, Wang ZJ, Mao WZ, Ma HC, Han JG, Zhao B, Xu HM. CXCR4/SDF-1 axis is involved in lymph node metastasis of gastric carcinoma. World J Gastroenterol 2011; 17: 2389-2396 [PMID: 21633638 DOI: 10.3748/wjg.v17.i19.2389]
157. Yasumoto K, Koizumi K, Kawashima A, Saitoh Y, Arita Y, Shinohara K, Minami T, Nakayama T, Sakurai H, Takahashi Y, Yoshie O, Saiki I. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res 2006; 66: 2181-2187 [PMID: 16489019 DOI: 10.1158/0008-5472. CAN-05-3393]
158. Ingold B, Simon E, Ungethüm U, Kuban RJ, Müller BM, Lupp A, Neumann U, Ebert MP, Denkert C, Weichert W, Schulz S, Röcken C. Vascular CXCR4 expression-a novel antiangiogenic target in gastric cancer? PLoS One 2010; 5: e10087 [PMID: 20386750 DOI: 10.1371/journal.pone.0010087]
159. Ishigami S, Natsugoe S, Okumura H, Matsumoto M, Nakajo A, Uenosono Y, Arigami T, Uchikado Y, Setoyama T, Arima H, Hokita S, Aikou T. Clinical implication of CXCL12 expression in gastric cancer. Ann Surg Oncol 2007; 14: 3154-3158 [PMID: 17653799 DOI: 10.1245/s10434-007-9521-6]
160. Nathoo N, Chahlavi A, Barnett GH, Toms SA. Pathobiology of brain metastases. J Clin Pathol 2005; 58: 237-242 [PMID: 15735152. DOI: 10.1136/jcp.2003.013623]
161. Krueger S, Hundertmark T, Kalinski T, Peitz U, Wex T, Malfertheiner P, Naumann M, Roessner A. Helicobacter pylori encoding the pathogenicity island activates matrix metalloproteinase 1 in gastric epithelial cells via JNK and ERK. J Biol Chem 2006; 281: 2868-2875 [PMID: 16321971 DOI: 10.1074/ jbc.M511053200]
162. Crawford HC, Krishna US, Israel DA, Matrisian LM, Washington MK, Peek RM. Helicobacter pylori strain-selective induction of matrix metalloproteinase-7 in vitro and within gastric mucosa. Gastroenterology 2003; 125: 1125-1136 [PMID: 14517796. DOI: 10.1016/S0016-5085(03)01206-X]
163. Wroblewski LE, Noble PJ, Pagliocca A, Pritchard DM, Hart CA, Campbell F, Dodson AR, Dockray GJ, Varro A. Stimulation of MMP-7 (matrilysin) by Helicobacter pylori in human gastric epithelial cells: role in epithelial cell migration. J Cell Sci 2003; 116: 3017-3026 [PMID: 12808021 DOI: 10.1242/ jcs.00518]
164. McCaig C, Duval C, Hemers E, Steele I, Pritchard DM, Przemeck S, Dimaline R, Ahmed S, Bodger K, Kerrigan DD, Wang TC, Dockray GJ, Varro A. The role of matrix metalloproteinase-7 in redefining the gastric microenvironment in response to Helicobacter pylori. Gastroenterology 2006; 130: 1754-1763 [PMID: 16697739 DOI: 10.1053/ j.gastro.2006.02.031]
165. Rautelin HI, Oksanen AM, Veijola LI, Sipponen PI, Tervahartiala TI, Sorsa TA, Lauhio A. Enhanced systemic matrix metalloproteinase response in Helicobacter pylori gastritis. Ann Med 2009; 41: 208-215 [PMID: 18979291 DOI: 10.1080/07 853890802482452]
166. Bergin PJ, Raghavan S, Svensson H, Starckx S, Van Aelst I, Gjertsson I, Opdenakker G, Quiding-Järbrink M. Gastric gelatinase B/matrix metalloproteinase-9 is rapidly increased in Helicobacter felis-induced gastritis. FEMS Immunol Med Microbiol 2008; 52: 88-98 [PMID: 17995959 DOI: 10.1111/j.1574-695X.2007.00349.x]
167. Wu JY, Lu H, Sun Y, Graham DY, Cheung HS, Yamaoka Y. Balance between polyoma enhancing activator 3 and activator protein 1 regulates Helicobacter pylori-stimulated matrix metalloproteinase 1 expression. Cancer Res 2006; 66: 5111-5120 [PMID: 16707434 DOI: 10.1158/0008-5472. CAN-06-0383]
168. Ogden SR, Wroblewski LE, Weydig C, Romero-Gallo J, O'Brien DP, Israel DA, Krishna US, Fingleton B, Reynolds AB, Wessler S, Peek RM. p120 and Kaiso regulate Helicobacter pylori-induced expression of matrix metalloproteinase-7. Mol Biol Cell 2008; 19: 4110-4121 [PMID: 18653469 DOI: 10.1091/mbc.E08-03-0283]
169. Yonemura Y, Endou Y, Fujita H, Fushida S, Bandou E, Taniguchi K, Miwa K, Sugiyama K, Sasaki T. Role of MMP-7 in the formation of peritoneal dissemination in gastric cancer. Gastric Cancer 2000; 3: 63-70 [PMID: 11984713 DOI: 10.1007/ PL00011698]
170. Yin Y, Grabowska AM, Clarke PA, Whelband E, Robinson K, Argent RH, Tobias A, Kumari R, Atherton JC, Watson SA. Helicobacter pylori potentiates epithelial: mesenchymal transition in gastric cancer: links to soluble HB-EGF, gastrin and matrix metalloproteinase-7. Gut 2010; 59: 1037-1045 [PMID: 20584780. DOI: 10.1136/gut.2009.199794]
171. Bergin PJ, Anders E, Sicheng W, Erik J, Jennie A, Hans L, Pierre M, Qiang PH, Marianne QJ. Increased production of matrix metalloproteinases in Helicobacter pylori-associated human gastritis. Helicobacter 2004; 9: 201-210 [PMID: 15165255. DOI: 10.1111/j.1083-4389.2004.00232.x]
172. Kubben FJ, Sier CF, Schram MT, Witte AM, Veenendaal RA, van Duijn W, Verheijen JH, Hanemaaijer R, Lamers CB, Verspaget HW. Eradication of Helicobacter pylori infection favourably affects altered gastric mucosal MMP-9 levels. Helicobacter 2007; 12: 498-504 [PMID: 17760717 DOI: 10.1111/ j.1523-5378.2007.00527.x]
173. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002; 115: 3719-3727 [PMID: 12235282 DOI: 10.1242/ jcs.00063]
174. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med 2008; 29: 258-289 [PMID: 18762209. DOI: 10.1016/j.mam.2008.08.001]
175. Yoshimura T, Tomita T, Dixon MF, Axon AT, Robinson PA, Crabtree JE. ADAMs (a disintegrin and metalloproteinase) messenger RNA expression in Helicobacter pylori-infected, normal, and neoplastic gastric mucosa. J Infect Dis 2002; 185: 332-340 [PMID: 11807715 DOI: 10.1086/338191]
176. Saha A, Backert S, Hammond CE, Gooz M, Smolka AJ. Helicobacter pylori CagL activates ADAM17 to induce repression of the gastric H, K-ATPase alpha subunit. Gastroenterology 2010; 139: 239-248 [PMID: 20303353 DOI: 10.1053/ j.gastro.2010.03.036]
177. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomized controlled trial. Lancet 2010; 376: 687-697 [DOI: 10.1016/S0140-6736(10)61121-X]
178. United Sates Food and Drug Administration. Herceptin (trastuzumab) [prescribing information]. Available from: URL: http://www.accessdata.fda.gov/drugsatfda_docs/ label/2010/103792s5250lbl.pdf Accessed October 26, 2011.
179. European Medicines Agency. Herceptin [summary of product characteristics]. Available from: URL: http://www. ema.europa.eu/docs/enMGB/document_library/EPAR_-_Product_Information/human/000278/WC500074922.pdf Accessed October 26, 2011.
180. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011; 29: 3968-3976 [PMID: 21844504 DOI: 10.1200/ JCO.2011.36.2236]
181. Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Giannetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C, Piana E, Martoni AA. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007; 18: 510-517 [PMID: 17164226 DOI: 10.1093/annonc/mdl459]
182. Moehler M, Mueller A, Trarbach T, Lordick F, Seufferlein T, Kubicka S, Geissler M, Schwarz S, Galle PR, Kanzler S. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol 2011; 22: 1358-1366 [PMID: 21119032 DOI: 10.1093/annonc/mdq591]
183. Richards D, Kocs DM, Spira AI, David McCollum A, Diab S, Hecker LI, Cohn A, Zhan F, Asmar L. Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study. Eur J Cancer 2013; 49: 2823-2831 [PMID: 23747051 DOI: 10.1016/ j.ejca.2013.04.022]
184. Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib. accessed January 21, 2012. Available from: URL: http//www.clinicaltrials.gov/ct/show/NCT00680901
185. Satoh T, Bang Y, Wang J. Interim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as second line therapy in gastric cancer. J Clin Oncol 2010; 28 suppl15: 4057
186. Bae SH, Ryoo HM, Kim MK, Lee KH, Sin JI, Hyun MS. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines. Oncol Rep 2008; 19: 1027-1032 [PMID: 18357392]
187. Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One 2013; 8: e54014 [PMID: 23516391 DOI: 10.1371/journal.pone.0054014]
188. Molife LR, Fong PC, Paccagnella L, Reid AH, Shaw HM, Vidal L, Arkenau HT, Karavasilis V, Yap TA, Olmos D, Spicer J, Postel-Vinay S, Yin D, Lipton A, Demers L, Leitzel K, Gualberto A, de Bono JS. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer 2010; 103: 332-339 [PMID: 20628389 DOI: 10.1038/ sj.bjc.6605767]
189. Squires M, Ward G, Saxty G, Berdini V, Cleasby A, King P, Angibaud P, Perera T, Fazal L, Ross D, Jones CG, Madin A, Benning RK, Vickerstaffe E, O'Brien A, Frederickson M, Reader M, Hamlett C, Batey MA, Rich S, Carr M, Miller D, Feltell R, Thiru A, Bethell S, Devine LA, Graham BL, Pike A, Cosme J, Lewis EJ, Freyne E, Lyons J, Irving J, Murray C, Newell DR, Thompson NT. Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models. Mol Cancer Ther 2011; 10: 1542-1552 [PMID: 21764904 DOI: 10.1158/1535-7163.MCT-11-0426]
190. Lang SA, Klein D, Moser C, Gaumann A, Glockzin G, Dahlke MH, Dietmaier W, Bolder U, Schlitt HJ, Geissler EK, Stoeltzing O. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther 2007; 6: 1123-1132 [PMID: 17363505 DOI: 10.1158/1535-7163.MCT-06-0628]
191. Weichert W, Röske A, Gekeler V, Beckers T, Ebert MP, Pross M, Dietel M, Denkert C, Röcken C. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008; 9: 139-148 [PMID: 18207460 DOI: 10.1016/ S1470-2045(08)70004-4]
192. Fetterly GJ, Brady WE, LeVea CM. A phase I pharmacokinetic (PK) study of vorinostat (V) in combination with irinotecan (I), 5-fluorouracil (5FU), and leucovorin (FOLFIRI) in advanced upper gastrointestinal cancers (AGC). J Clin Oncol 2009; 27 suppl15: el5540
193. Chiba T, Marusawa H, Seno H, Watanabe N. Mechanism for gastric cancer development by Helicobacter pylori infection. J Gastroenterol Hepatol 2008; 23: 1175-1181 [PMID: 18637055 DOI: 10.1111/j.1440-1746.2008.05472.x]